The Impact of COVID-19 Research on the Development of Scalable Frameworks for Efficient Clinical Trials in Cardiovascular Medicine.

The COVID-19 pandemic has spurred the demand for prompt evaluation of possible treatments. Conventional clinical trial timelines for evidence generation are therefore inadequate. One of the most effective solutions has been the deployment of platform trials, which enable the simulta-neous investigation of multiple therapeutic strategies. Plat-form trials operate under a comprehensive master protocol that standardises critical design and operational aspects and incorporate adaptive elements that enable modifications to the trial in response to its own data. Although platform trials and adaptive designs have been implemented in other fields, such as oncology, opportunity remains for their broader adoption in cardiovascular medicine.